Experience

• • Glendower Capital in the formation of its Secondary Opportunities Fund V, a $5.8 billion global secondary private equity fund.
  • HarbourVest Partners as co-lead investor in a $1 billion continuation fund, sponsored by OEP, to support continued growth for two European portfolio companies.
  • CPP Investments as an investor in a single-asset continuation fund established by GHO Capital Partners, created to hold existing portfolio company Validant, a leading international provider of quality, compliance and regulatory affairs consulting to Biotech, Pharma and MedTech companies.
  • Carlyle in its acquisition of Abingworth, a transatlantic life sciences investment firm with over $2 billion in assets under management.
  • First Reserve in its role as a strategic investor in Venterra Group, the offshore wind energy services business, as part of Venterra’s third funding round.
  • Fifth Wall in the formation of its European Real Estate Technology Fund, a €140 million fund targeting investments in high-potential European startups, and potential co-investing opportunities alongside Fifth Wall’s North American Real Estate Tech funds.
  • Clayton, Dubilier & Rice in its acquisition of PwC’s Global Mobility Tax and Immigration Services practice, the global leader in employee tax, immigration, business travel, cross-border managed services, and payroll solutions to multinational organizations and their employees.
  • Glendower Capital in its strategic partnership with CVC, creating a combined group with total assets under management of approximately €113 billion.
  • Asta Capital and its shareholders, the market leading third party managing agent at Lloyd’s, in its sale to Davies Group.
  • A major international financial investor in the formation of a €1 billion+ global infrastructure fund.
  • LeapFrog Investments in its $500 million partnership with Temasek, including Temasek taking a minority stake in LeapFrog, and a multi-fund investment by Temasek to anchor LeapFrog’s future funds.
  • Pantheon and LGT Capital Partners as lead investors in a continuation vehicle sponsored by Medicxi, a European life sciences investor, involving six preclinical- and clinical-stage assets.
  • Pantheon in its equity investment as part of the proposed £2 billion takeover by KKR of John Laing Group plc.
  • A consortium of private equity investors in the proposed acquisition through a competitive auction of equity interests in a privately-held insurance company in China.